Lasmotinib
Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer[1][2][3][4].
Product Specifications
CAS Number
2127107-15-5
Product Name Alternative
PHI-101
UNSPSC
12352005
Target
Checkpoint Kinase (Chk) ; FLT3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/phi-101.html
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC(NC1=C(SC(C#CC2=CC(F)=CC=C2)=C1)C(N[C@H]3CCCNC3)=O)=O
Molecular Formula
C19H19FN4O2S
Molecular Weight
386.44
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Chk2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
C9orf95 (NMRK1) (NM_001127603) Human Over-expression Lysate
